Leap Therapeutics, Inc. (LPTX) 是一家上市公司 属于 医疗保健 板块，经营于 生物科技 行业. 公司总部位于 Cambridge, MA, 美国. 现任CEO为 Douglas E. Onsi.
LPTX 拥有 IPO日期为 2017-01-25, 52 名全职员工, 在 NASDAQ Global Market, 市值为 $31.86M.
Leap Therapeutics, Inc., a biopharmaceutical company, acquires and develops therapies for the treatment of cancer. Its lead clinical stage programs include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in multiple ongoing clinical trials for treating esophagogastric, hepatobiliary, gynecologic, and prostate cancers. Leap Therapeutics, Inc. has an option and license agreement with BeiGene, Ltd. to develop and commercialize DKN-01 in Asia (excluding Japan), Australia, and New Zealand. The company was formerly known as HealthCare Pharmaceuticals, Inc. and changed its name to Leap Therapeutics, Inc. in November 2015. Leap Therapeutics, Inc. was incorporated in 2011 and is based in Cambridge, Massachusetts.
